Analysts Set QIAGEN N.V. (NYSE:QGEN) Price Target at $49.40

Key Points

• Qiagen N.V. has received an average rating of "Hold" from ten analysts, with seven recommending a hold and three a buy.
• The company's average one-year price target is $49.40, while Barclays recently set a more optimistic target of $55.00.
• Qiagen reported a 5.2% year-over-year revenue increase, with a quarterly revenue of $483.46 million and earnings per share of $0.55.

Shares of QIAGEN N.V. (NYSE:QGEN - Get Free Report) have earned an average recommendation of "Hold" from the ten research firms that are presently covering the company, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $49.40.

Several equities analysts recently commented on the company. Bank of America boosted their price target on QIAGEN from $50.00 to $53.00 and gave the stock a "buy" rating in a research report on Thursday, June 26th. Barclays initiated coverage on QIAGEN in a research report on Tuesday, June 24th. They set an "overweight" rating and a $55.00 price target on the stock. Wall Street Zen lowered QIAGEN from a "strong-buy" rating to a "buy" rating in a research report on Saturday, July 26th. Redburn Atlantic lowered QIAGEN from a "buy" rating to a "neutral" rating in a research report on Friday, April 4th. Finally, Robert W. Baird upped their target price on QIAGEN from $42.00 to $43.00 and gave the company a "neutral" rating in a research report on Monday, April 21st.

QIAGEN Trading Down 0.8%

Shares of NYSE:QGEN traded down $0.42 during trading on Monday, reaching $50.15. 425,745 shares of the stock were exchanged, compared to its average volume of 1,363,764. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.83 and a current ratio of 3.37. QIAGEN has a 12-month low of $37.63 and a 12-month high of $51.88. The firm has a market cap of $11.15 billion, a price-to-earnings ratio of 125.74, a price-to-earnings-growth ratio of 2.59 and a beta of 0.68. The firm's 50-day moving average price is $47.08 and its 200 day moving average price is $43.31.

QIAGEN (NYSE:QGEN - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.55 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.50 by $0.05. The business had revenue of $483.46 million during the quarter, compared to analysts' expectations of $465.66 million. QIAGEN had a return on equity of 14.61% and a net margin of 4.68%. The company's revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.44 EPS. On average, sell-side analysts anticipate that QIAGEN will post 2.26 earnings per share for the current fiscal year.

QIAGEN Announces Dividend

The firm also recently declared a dividend, which was paid on Thursday, July 10th. Stockholders of record on Thursday, July 3rd were paid a $0.25 dividend. The ex-dividend date of this dividend was Wednesday, July 2nd. This represents a dividend yield of 0.52%. QIAGEN's payout ratio is 62.50%.

Institutional Trading of QIAGEN

Several institutional investors have recently modified their holdings of the company. SVB Wealth LLC purchased a new stake in shares of QIAGEN during the first quarter valued at $31,000. Brown Brothers Harriman & Co. bought a new position in QIAGEN during the fourth quarter valued at approximately $37,000. Farther Finance Advisors LLC raised its position in QIAGEN by 400.5% during the second quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company's stock valued at $51,000 after acquiring an additional 849 shares in the last quarter. Cullen Frost Bankers Inc. raised its position in QIAGEN by 13,144.4% during the second quarter. Cullen Frost Bankers Inc. now owns 1,192 shares of the company's stock valued at $57,000 after acquiring an additional 1,183 shares in the last quarter. Finally, Hilltop National Bank bought a new position in QIAGEN during the second quarter valued at approximately $66,000. Institutional investors and hedge funds own 70.00% of the company's stock.

About QIAGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.